GLP-1 Side Effects: The Complete Guide to Managing Them

The most common GLP-1 side effects are nausea, constipation, diarrhea, and fatigue — usually mild, concentrated in the first weeks after a dose change, and manageable with food and hydration adjustments. Here is what to expect on compounded semaglutide or tirzepatide, and when a symptom is worth a provider conversation.

What are the most common GLP-1 side effects?

Nausea

Nausea is the most frequently reported side effect, affecting roughly 30-40% of new users. It's typically worst during the first few weeks and during dose escalation periods.

Why it happens: GLP-1 receptors are present in the stomach and brain. Semaglutide slows gastric emptying (food moves more slowly through your stomach), which can trigger nausea, especially after larger meals.

What helps:

• Eat smaller, more frequent meals
• Avoid high-fat or greasy foods during the first month
• Stay hydrated by sipping water rather than drinking large amounts at once
• Take your injection at night so any nausea occurs while you sleep

Constipation

Because GLP-1 medications slow gut motility, constipation is common, especially in the first 2-4 weeks.

What helps:

• Increase fiber intake (vegetables, legumes, whole grains)
• Drink at least 2-3 liters of water daily
• Gentle movement like walking stimulates digestion
• A daily magnesium supplement (200-400mg) can help

Fatigue

Some patients experience low energy in the first 1-2 weeks. This is usually related to reduced caloric intake rather than the medication itself.

What helps:

• Make sure you're getting adequate protein — our guide on why protein matters on a GLP-1 covers targets and food choices
• Don't cut calories too aggressively. Let the medication moderate your appetite naturally
• Maintain consistent sleep habits

What less common side effects should you watch for?

Vomiting

Vomiting is less common than nausea but does occur, usually in the context of overeating or eating too quickly. If it persists beyond the adjustment period, contact your provider to discuss a slower titration schedule.

Headaches

Mild headaches during the first few weeks are often caused by dehydration or reduced food intake. Increase water intake and ensure you're eating regularly.

Injection Site Reactions

Redness, mild swelling, or bruising at the injection site is normal and temporary. Rotating injection sites (abdomen, thigh, upper arm) and allowing the medication to reach room temperature before injecting helps minimize this.

When should you contact your provider?

Reach out to your provider through your patient portal immediately if you experience:

• Severe abdominal pain that radiates to the back, which can rarely indicate pancreatitis
• Persistent vomiting that prevents you from keeping liquids down
• Signs of allergic reaction including rash, difficulty breathing, or rapid heartbeat
• Changes in vision if you have a history of diabetic retinopathy

These are rare but require prompt medical attention.

Why does slow titration matter?

Providers typically use a slow titration schedule specifically to minimize side effects. Rather than starting at the full therapeutic dose, most patients begin at 0.25 mg per week and increase roughly every 4 weeks based on tolerance.

Most side effects are dose-dependent, meaning they're most likely to occur right after a dose increase. If side effects are significant at any stage, your provider can hold the current dose longer before escalating — how the ongoing care loop works is built around exactly these check-ins.

How long does the adjustment period last?

The good news: for most people, GLP-1 side effects are temporary. The majority of patients who experience nausea find it resolves significantly within 4-6 weeks of starting or after a dose adjustment.

Your body is adapting to a new hormonal signal. Give it time, follow your provider's titration plan, and keep your provider informed through the patient portal. The outcome - sustained weight loss with dramatically reduced hunger - is worth the short-term adjustment for most people.